EcoDrugPlus

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSSTUG00000015945
Gene Symbol: PSMD2
3 Cross references
216 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSSTUG00000003015
Gene Symbol: PSMD2
3 Cross references
215 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSSTUG00000034773
Gene Symbol: PSMD4
3 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSSTUG00000041012
Gene Symbol: PSMD4
1 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSSTUG00000033260
Gene Symbol: PSMC1
3 Cross references
32 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSSTUG00000015056
Gene Symbol: PSMC1
3 Cross references
77 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSSTUG00000050624
Gene Symbol: PSMC1
1 Cross references
209 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSSTUG00000034931
Gene Symbol: PSMC5
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSSTUG00000016610
Gene Symbol: PSMD1
3 Cross references
208 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSSTUG00000027628
Gene Symbol: PSMD11
3 Cross references
201 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSSTUG00000009233
Gene Symbol: PSMD11
3 Cross references
200 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSSTUG00000046866
Gene Symbol: PSMD6
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).